We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

Viatris emerged from Pfizer's merger with Mylan and Upjohn, trading since 2020, with a market cap of $11 billion. See why I ...

NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Shares of Viatris Inc. VTRS slid 2.81% to $8.98 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.39% to 5,521.52 and Dow ...

Viatris Inc. missed sales/EPS estimates with 2025 guidance showing challenges like a $385M EBITDA hit. Learn why experts suggest avoiding VTRS stock.

Viatris issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods. The most recent guidance for Viatris (VTRS) was reported ...

Shares of Viatris Inc. VTRS slipped 1.07% to $9.24 Wednesday, on what proved to be an all-around mixed trading session for ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other ...